Relapsed chronic lymphocytic leukemia retreated with rituximab: interim results of the PERLE study-Reference-Cited by-同舟云学术

Relapsed chronic lymphocytic leukemia retreated with rituximab: interim results of the PERLE study

Published:2017-02-09 Issue:6 Volume:58 Page:1366-1375
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Chaoui Driss¹,Choquet Sylvain²,Sanhes Laurence³,Mahé Béatrice⁴,Hacini Maya⁵,Fitoussi Olivier⁶,Arkam Yazid⁷,Orfeuvre Hubert⁸,Dilhuydy Marie-Sarah⁹,Barry Marly¹⁰,Jourdan Eric¹¹,Dreyfus Brigitte¹²,Tempescul Adrian¹³,Leprêtre Stéphane¹⁴,Bardet Aurélie¹⁵,Leconte Pierre¹⁵,Maynadié Marc¹⁶,Delmer Alain¹⁷

Affiliation:

1. Hématologie, Centre hospitalier Victor Dupouy, Argenteuil, France;

2. Hématologie, Hôpital La Pitié Salpêtrière, Paris, France;

3. Hématologie, Hôpital Saint-Jean, Perpignan, France;

4. Hématologie, CHU de Nantes, Nantes, France;

5. Hématologie, Centre hospitalier de Chambéry, Chambéry, France;

6. Hématologie, Polyclinique Bordeaux Nord, Bordeaux, France;

7. Hématologie, Hôpital Emile Muller, Mulhouse, France;

8. Hématologie, Centre hospitalier de Fleyriat, Bourg en Bresse, France;

9. Hématologie, Hôpitaux de Bordeaux Pessac, Hôpital Haut Levêque, France;

10. Hématologie, Centre hospitalier du Dr Duchenne, Boulogne sur Mer, France;

11. Hématologie, CHU de Nîmes, Nîmes, France;

12. Hématologie, Pôle Régional de Cancérologie, Poitiers, France;

13. Hématologie, Hôpital Auguste Morvan, Brest, France;

14. Hématologie, Centre Henri Becquerel, Rouen, France;

15. Medical Affairs, Roche France, Boulogne-Billancourt, France;

16. Hématologie, CHU du Bocage, Dijon, France;

17. Hématologie, CHU Robert Debré, Reims, France

Funder

The study is funded by Roche, France

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

https://www.tandfonline.com/doi/pdf/10.1080/10428194.2016.1243673

Reference41 articles.

1. WHO. 2014. Chronic lymphocytic leukemia – Union for International Cancer Control – Review of Cancer Medicines on the WHO List of Essential Medicines.

2. Monnereau A, Remontet L, Maynadié M, et al. Estimation nationale de l’incidence des cancers en france entre 1980 et 2012. Partie 2 – hémopathies malignes. Saint-Maurice (France): Institut de veille sanitaire; 2013. p. 88. French.

3. Chronic lymphocytic leukemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

4. Chronic Lymphocytic Leukemia

5. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real-world use and acceptance of rituximab biosimilars in non-Hodgkin lymphoma in an oncologist network in Germany;Future Oncology;2020-05

2. Possible hampered effectiveness of second-line treatment with rituximab-containing chemotherapy without signs of rituximab resistance: a population-based study among patients with chronic lymphocytic leukemia;Annals of Hematology;2020-03-19

3. Relapsed or refractory chronic lymphocytic leukemia retreated with rituximab in daily practice: final results of the PERLE study;Leukemia & Lymphoma;2019-01-09

4. Glycosylation of Recombinant Anticancer Therapeutics in Different Expression Systems with Emerging Technologies;Cancer Research;2018-05-22